Business Description
Climb Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US28658R1068
Compare
Compare
Traded in other countries / regions
CLYM.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2021-08-10Description
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 206.88 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.9 | |||||
| 3-Year EPS without NRI Growth Rate | 52.4 | |||||
| 3-Year FCF Growth Rate | 52.1 | |||||
| 3-Year Book Growth Rate | -20.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -25.21 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.91 | |||||
| 9-Day RSI | 42.92 | |||||
| 14-Day RSI | 45.2 | |||||
| 3-1 Month Momentum % | -1.67 | |||||
| 6-1 Month Momentum % | -34.44 | |||||
| 12-1 Month Momentum % | -83.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.25 | |||||
| Quick Ratio | 14.25 | |||||
| Cash Ratio | 13.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.9 | |||||
| Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -48.8 | |||||
| ROA % | -47.66 | |||||
| ROIC % | -267.7 | |||||
| 3-Year ROIIC % | 16.72 | |||||
| ROC (Joel Greenblatt) % | -47019.82 | |||||
| ROCE % | -53.51 | |||||
| Moat score | 3 | |||||
| Tariff score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.44 | |||||
| Price-to-Tangible-Book | 0.44 | |||||
| EV-to-EBIT | 0.17 | |||||
| EV-to-EBITDA | 0.17 | |||||
| EV-to-FCF | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 0.91 | |||||
| Price-to-Net-Cash | 0.94 | |||||
| Earnings Yield (Greenblatt) % | 588.24 | |||||
| FCF Yield % | -34.27 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers